Hard to Treat Diseases (Hard to Treat Diseases) EPS (Diluted) : $ (TTM As of . 20)

Hard to Treat Diseases EPS (Diluted) Chart

Competitive Comparison of Hard to Treat Diseases's EPS (Diluted)

For the Biotechnology subindustry, Hard to Treat Diseases's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hard to Treat Diseases's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's PE Ratio distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's PE Ratio falls into.

Hard to Treat Diseases EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Hard to Treat Diseases's Diluted EPS for the fiscal year that ended in . 20 is calculated as

Hard to Treat Diseases's Diluted EPS for the quarter that ended in . 20 is calculated as

Hard to Treat Diseases  (OTCPK:HTDS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hard to Treat Diseases EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hard to Treat Diseases (Hard to Treat Diseases) Business Description